Tasipimidine And Cyp2 D6 Inhibitor Combination Treatment

The invention relates to co administration a CYP2D6 inhibitor with tasipimidine or a pharmaceutically acceptable salt thereof in order to improve the pharmacokinetic profile of tasipimidine by decreasing its clearance and inter individual variation. The invention also relates to a combination of tasipimidine or a pharmaceutically acceptable salt thereof and a CYP2D6 inhibitor and the use of such a combination for the treatment of a disorder condition or disease where an alpha2A agonist is indicated to be useful for example for use in the treatment of neuropsychiatric disorders.